A Multicentric Observational Study on Azilsartan to Assess the Efficacy, Safety and Tolerability in the Management of Hypertension in Indian Population: ZEAL Study
Published: 2024-05-13
Page: 71-78
Issue: 2024 - Volume 7 [Issue 1]
Uday M Jadhav
MGM New Bombay Hospital, Mumbai, Maharashtra, India.
B C Kalmath
Bombay Hospital Institute of Medical Science, Mumbai, Maharashtra, India.
Manjula S *
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
Krishna Kumar M
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Background: Azilsartan is a recently approved angiotensin receptor blocker (ARB) available for the treatment of hypertension in India. Azilsartan has demonstrated unique properties which are different from the previous ARBs. The study objective was to assess the efficacy, safety of azilsartan in Indian subjects with hypertension.
Methodology: The ZEAL study (AZilsartan Efficacy, SAfety and ToLerability Study) was an open label, non-comparative, multi-centric, observational study in Indian adult hypertensive patients. 152 centres were included in this study from across India by convenience sampling. Informed consent was taken from all participating subjects. Azilsartan 80 mg once daily was administered for 12 weeks. The primary outcome measure was decrease in mean seated systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the end of 12 weeks from the baseline value. The secondary outcome measure included Global assessment of efficacy as evaluated by physician using a 4-point scale.
Results: A total of 4560 subjects were recruited in the study, 30 subjects each from 152 centres. 4416 subjects completed the 12-weeks study. Among them 2881 (65.3 %) were men and 1535 (34.7%) women. Mean age of the subjects during the recruitment was 53.6 ± 10.79 years. In our study, at the baseline, the mean SBP and mean DBP was 152.33 ± 16.39 mm Hg and 94.06±8.74 mm Hg respectively. At 6 weeks, the mean SBP was 143.9±13.6 mm Hg (∆8.43 ± 4.1 mm Hg) and 133.7±9.2 mm Hg (∆18.63±7.2 mm Hg) at the end of 12-weeks study which was clinically and statistically significant (P<0.05). Azilsartan was well tolerated. Global assessment of efficacy as evaluated by physician using a 4-point scale was very good or excellent for 77.8% of the study subjects.
Conclusion: Azilsartan effectively reduced SBP and DBP in the study subjects and was well tolerated. Azilsartan is a valuable option for achieving BP targets.
Keywords: Hypertension, azilsartan, angiotensin receptor blocker, blood pressure
How to Cite
References
Singh PS, Singh PK, Zafar KS, Sharma H, Yadav SK, Gautam RK, Pious T et al. Prevalence of hypertension in rural population of Central India. Int J Res Med Sci. 2017, Apr;5(4):1451-1455.
Bharatia R, Chitale M, Saxena GN, Kumar RG, Chikkalingaiah, Trailokya A et al. Management practices in indian patients with uncontrolled hypertension. J Assoc Physicians India. 2016, Jul;64(7):14-21.
Pilakkadavath Z, Shaffi M. Modifiable risk factors of hypertension: A hospital-based case-control study from Kerala, India. J Family Med Prim Care. 2016, Jan-Mar;5(1):114-9.
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017, Jan 10;317(2): 165-182.
Khanal MK, Dhungana RR, Bhandari P, Gurung Y, Paudel KN. Prevalence, associated factors, awareness, treatment, and control of hypertension: Findings from a cross sectional study conducted as a part of a community based intervention trial in Surkhet, Mid-western region of Nepal. Plos One. 2017, Oct 5;12(10): e0185806.
Ferrari R. RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract. 2013;(3):34.
Kalaitzidis R, Bakris G. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009;11(6):436-42.
Novo S, Lunetta M, Evola S, Novo G. Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events. Curr Drug Targets. 2009;10(1):20-25.
Kurtz T, Kajiya, Kurtz. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. VHRM. 2012;133.
Jones JD, Jackson SH, Agboton C, Martin TS. Azilsartan medoxomil (Edarbi): The eighth angiotensin II receptor blocker. P T. 2011;36(10):634-40.
Anchala R, Kannuri N, Pant H, Khan H, Franco O, Di Angelantonio E et al. Hypertension in India. J Hypertens. 2014; 32(6):1170-77.
Maharjan B. Prevalence and awareness of hypertension among adults and its related risk factors. J Nepal Health Res Counc. 2018, Jan 1;15(3):242-246.
Gao K, Shi X, Wang W. The life- course impact of smoking on hypertension, myocardial infarction and respiratory diseases. Sci Rep. 2017, Jun 28;7(1): 4330.
White W, Weber M, Sica D, Bakris G, Perez A, Cao C et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3): 413-20.
Bakris G, Sica D, Weber M, White W, Roberts A, Perez A, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens. 2011;13(2):81-88.
Weber M, White W, Sica D, et al. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014; 19(2):90-97.
Juhasz A, Wu J, Hisada M, Tsukada T, Jeong MH. Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension. Clin Hypertens. 2018, Feb 7;24:2.